Pharmahungary Group joins COST Action titled CardioRNA – “Catalyzing transcriptomics research in cardiovascular disease”. The COST Action was proposed by Cardiolink Board Members and co-proposed by other 19 Cardiolinc members and partners.

The aim of the CardioRNA COST Action is to accelerate the understanding of transcriptomics in cardiovascular disease and further the translation of experimental data into practical applications for diagnostics and therapies to improve personalized medicine.

The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. CardioRNA aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic.